Skip to main content

FDA Approvals

FDA Approvals
Mayzent (Siponimod) Approved for Relapsing Forms of Multiple Sclerosis, Including Active Secondary Progressive Disease
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
Pemazyre (Pemigatinib) First Targeted Therapy FDA Approved for Cholangio­carcinoma with FGFR2 Biomarker
Loretta Fala
Read More
FDA Approvals
Tazverik (Tazemetostat) First FDA-Approved Treatment Specifically for Patients with Epithelioid Sarcoma
Loretta Fala
Read More
FDA Approvals
Trodelvy (Sacituzumab Govitecan-hziy) a New Targeted Therapy for Patients with Metastatic Triple-Negative Breast Cancer
Loretta Fala
Read More
FDA Approvals
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
Loretta Fala
Read More
FDA Approvals
FDA Approvals of Brand-Name Prescription Drugs, January 1, 2019, Through June 15, 2020
Read More
FDA Approvals
FDA News: August 2020
Read More
FDA Approvals
Tumor-Infiltrating Lymphocyte Therapy Induces Responses Across Wide Range of Patients with Advanced Melanoma
Wayne Kuznar
Wayne Kuznar
Read More
FDA Approvals
The WEE1 Inhibitor Adavosertib Displays Promising Clinical Activity in Uterine Serous Cancer
Wayne Kuznar
Wayne Kuznar
Read More
FDA Approvals
Intratumoral Injection of Cisplatin and Vinblastine, with or without Pembrolizumab, Improves Intracellular Transport in Patients with Advanced Solid Tumors
Chase Doyle
Chase Doyle
Read More
Page 16 of 53
Results 151 - 160 of 527